Please login to the form below

Not currently logged in
Email:
Password:

HER2 inhibitor

This page shows the latest HER2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Strong five-year survival data for Kisqali in breast cancer

Strong five-year survival data for Kisqali in breast cancer

Novartis’ Kisqali plus letrozole offers more than a year survival benefit for postmenopausal women with HR+/HER2 advanced breast cancer. ... Kisqali is approved in the US and EU as initial endocrine-based therapy in combination with an aromatase

Latest news

More from news
Approximately 2 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is highly selective for

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    440. OncoEthix / Merck &Co. Lead product oral BET inhibitor, OTX015 for oncology indications (p1b). ... ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1).

  • Pharma deals during April 2014 Pharma deals during April 2014

    GSK's recently approved MEK inhibitor Mekinist and BRAF inhibitor Tafinlar will position Novartis to become a leader in the potential blockbuster market for metastatic melanoma, neglected by their current portfolio. ... Additional GSK products include

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...